Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Mankind Pharma's FCF Margin % or its related term are showing as below:
BOM:543904'
s FCF Margin % Range Over the Past 10 Years
Min: -18.32 Med: 14.35 Max: 17.19
Current: 16.7
During the past 7 years, the highest FCF Margin % of Mankind Pharma was 17.19%. The lowest was -18.32%. And the median was 14.35%.
BOM:543904's FCF Margin % is ranked better than 84.32% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.55
vs BOM:543904: 16.70
Mankind Pharma FCF Margin % Related Terms
Mankind Pharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Mankind Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mankind Pharma (BOM:543904) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mankind Pharma and its competitors. According to the industry distribution chart, Mankind Pharma ranks #151 out of 963 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is Mankind Pharma's FCF Margin % too high?
Mankind Pharma's current FCF Margin % is 0.00%. Based on the distribution chart, Mankind Pharma ranks #151 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mankind Pharma has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mankind Pharma ranks #151 out of 963 companies for FCF Margin %. This places Mankind Pharma in the top 16% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.55, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mankind Pharma and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mankind Pharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,933.99, compared to a current price of ₹2,491.45 — trading 15.1% below its estimated fair value. The current FCF Margin % is 0.00%. Mankind Pharma's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mankind Pharma (BOM:543904) Overvalued in 2026?
Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued.
The current stock price of ₹2,491.45 is trading 15.1% below its estimated GF Value™ of ₹2,933.99.
GuruFocus considers Mankind Pharma to be Modestly Undervalued.
Key valuation signals for BOM:543904:
FCF Margin %: 0.00%
GF Value™: ₹2,933.99 vs. price of ₹2,491.45 (15.1% below fair value)
No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
90GF Score
Get the complete analysis for BOM:543904
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543904 has been successfully added to your 
